ATE326479T1 - Varianten von antigenen des menschlichen papillomvirus - Google Patents

Varianten von antigenen des menschlichen papillomvirus

Info

Publication number
ATE326479T1
ATE326479T1 AT95941988T AT95941988T ATE326479T1 AT E326479 T1 ATE326479 T1 AT E326479T1 AT 95941988 T AT95941988 T AT 95941988T AT 95941988 T AT95941988 T AT 95941988T AT E326479 T1 ATE326479 T1 AT E326479T1
Authority
AT
Austria
Prior art keywords
variants
papilloma virus
human papilloma
virus antigens
hpv
Prior art date
Application number
AT95941988T
Other languages
English (en)
Inventor
Stirling John Edwards
John Cooper Cox
Elizabeth Ann Webb
Ian Frazer
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE326479T1 publication Critical patent/ATE326479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95941988T 1994-12-20 1995-12-20 Varianten von antigenen des menschlichen papillomvirus ATE326479T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN0157A AUPN015794A0 (en) 1994-12-20 1994-12-20 Variants of human papilloma virus antigens

Publications (1)

Publication Number Publication Date
ATE326479T1 true ATE326479T1 (de) 2006-06-15

Family

ID=3784665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941988T ATE326479T1 (de) 1994-12-20 1995-12-20 Varianten von antigenen des menschlichen papillomvirus

Country Status (10)

Country Link
US (3) US6004557A (de)
EP (1) EP0796273B1 (de)
JP (1) JPH10510989A (de)
AT (1) ATE326479T1 (de)
AU (2) AUPN015794A0 (de)
CA (2) CA2419289A1 (de)
DE (1) DE69534995T2 (de)
NZ (1) NZ297946A (de)
WO (1) WO1996019496A1 (de)
ZA (1) ZA9510832B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ES2191929T3 (es) * 1997-08-05 2003-09-16 Stressgen Biotechnologies Corp Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2264176A1 (de) 1997-12-10 2010-12-22 CSL Limited Polypeptiden und Nukleinsäuren von Phorphorymonas gingivalis
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
PL343429A1 (en) * 1998-03-09 2001-08-13 Smithkline Beecham Biolog Combined vaccine compositions
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
FR2781158B1 (fr) * 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
CA2342289C (en) * 1998-09-04 2012-07-24 Aventis Pasteur Limited Treatment of cervical cancer
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
TR200100936T2 (tr) 1998-10-05 2001-08-21 Pharmexa A/S Terapötik aşılama
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
JP2003504074A (ja) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
PT1214097E (pt) * 1999-09-16 2009-10-19 Eisai Inc Ácidos nucleicos que codificam polipéptidos de poliepitopos
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2408830A1 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
CA2415763A1 (en) * 2000-07-07 2002-01-17 Merck & Co., Inc. Production of chimeric human papillomavirus
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
CA2441947C (en) * 2001-03-23 2014-05-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreactive peptides
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2463960A1 (en) * 2001-10-18 2003-05-01 Heart Biosystems Gmbh Transient immortalization
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
WO2004025259A2 (en) 2002-09-12 2004-03-25 Molecular Probes, Inc. Site-specific labeling of affinity tags in fusion proteins
WO2004030636A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
KR100525321B1 (ko) * 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
EP1819835B1 (de) 2004-12-08 2010-08-04 Gen-Probe Incorporated Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
CA2598090A1 (en) * 2005-02-17 2006-08-24 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Synergistic effect of tgf-beta blockade and immunogenic agents on tumors
CN101421306B (zh) * 2006-04-19 2013-09-18 浦项工科大学校产学协力团 用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物
EP2013229A2 (de) * 2006-04-21 2009-01-14 Transgene S.A. Auf hpv-18 basierender papillomavirusimpfstoff
RU2008145712A (ru) * 2006-04-21 2010-05-27 Трансжене С.А (Fr) Вакцина против папилломовирусной инфекции на основе вируса папиломы человека впч-16
JP2009544333A (ja) * 2006-07-28 2009-12-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2655687T3 (es) 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
EP3730943A1 (de) 2010-04-08 2020-10-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
EP2604629B1 (de) * 2010-08-13 2018-02-28 Genexine, Inc. Zusammensetzung zur prävention oder behandlung von gebärmutterhalskrebs mit hpv-immunitätsverstärker
US9901635B2 (en) 2011-12-21 2018-02-27 Vaccibody As Vaccines against HPV
BR112017002809A2 (pt) 2014-08-15 2017-12-19 Genexine Inc métodos para tratar câncer cervical
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
RU2017132190A (ru) 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
US20180228885A1 (en) * 2016-03-04 2018-08-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
CA3024331A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
WO2018076008A1 (en) * 2016-10-21 2018-04-26 The Research Foundation For The State University Of New York Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
EP4138900A4 (de) 2020-04-24 2024-05-15 Genexine Inc Verfahren zur behandlung von gebärmutterhalskrebs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593860A (en) * 1987-08-14 1997-01-14 Bio-Technology General Corp. Expression plasmids containing the deo promoter, and bacterial hosts containing the plasmids
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
WO1992005248A1 (en) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
WO1992010513A1 (en) * 1990-12-12 1992-06-25 The University Of Queensland Subunit papillomavirus vaccine and peptides for use therein
WO1992016638A1 (en) 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein

Also Published As

Publication number Publication date
JPH10510989A (ja) 1998-10-27
AU4322996A (en) 1996-07-10
NZ297946A (en) 2000-01-28
WO1996019496A1 (en) 1996-06-27
US6303128B1 (en) 2001-10-16
EP0796273B1 (de) 2006-05-17
DE69534995D1 (de) 2006-06-22
AU693627B2 (en) 1998-07-02
US6004557A (en) 1999-12-21
CA2419289A1 (en) 1996-06-27
ZA9510832B (en) 1996-07-04
AUPN015794A0 (en) 1995-01-19
EP0796273A4 (de) 2001-11-28
CA2207741C (en) 2003-04-22
EP0796273A1 (de) 1997-09-24
US6306397B1 (en) 2001-10-23
CA2207741A1 (en) 1996-06-27
DE69534995T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
DK0759935T3 (da) Rekombinant papillomavirus L1
HUP0004327A1 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
NO933126D0 (no) Loeselige ligander for cd40
ATE207495T1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
ATE229978T1 (de) Helicobacter proteine und impstoffe
WO2000075336A3 (fr) Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
FI965224A (fi) Polynukleotidirokote papilloomavirukselle
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
ATE288489T1 (de) Vp-antigene des jc-virus
DE69519856T2 (de) Expression von albumin in hefe
EP0245433A4 (de) Wichtigstes protein von neisseria gonorrhöe mit eisenregelung und dessen verwendung.
EP1375511A3 (de) Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
EP0853486A4 (de) Therapeutische anwendungen von tierischen seren einschliesslich von pferdeseren in der behandlung von aids, krebs, und anderen viralen oder bakteriellen erkrankungen
DE3685651T2 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ATE459248T1 (de) Tiermodell zur berechnung von impstoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties